Wright W B, Tomcufcik A S, Chan P S, Marsico J W, Press J B
CNS-Cardiovascular Disease Research Section, Medical Research Division of American Cyanamid Company, Lederle Laboratories, Pearl River, New York 10965.
J Med Chem. 1987 Dec;30(12):2277-83. doi: 10.1021/jm00395a016.
The quinazolinedione, quinazolinone, and 1,2,3-benzotriazinone title compounds were prepared as analogues of N-[(1H-imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones which were the subject of a previous report from our laboratories. These compounds were evaluated as thromboxane (TX) synthetase inhibitors and as antihypertensive agents. While each series of compounds had activity both as TX synthetase inhibitors and as antihypertensives, the best compounds were N-[(1H-imidazol-1-yl)alkyl]quinazoline-2,4(1H,3H]-diones (V). In general these compounds were all selective enzyme inhibitors at least equipotent with the standard dazoxiben. These compounds were also very active antihypertensive agents as determined in SHR. The SAR is discussed for both types of activity. Compound 20a was further evaluated for TX formation inhibiting properties in several other platelet types both in vitro and ex vivo and is between 100 and 1000 times more potent than dazoxiben.
喹唑啉二酮、喹唑啉酮和1,2,3-苯并三嗪酮类目标化合物是作为N-[(1H-咪唑-1-基)烷基]-1H-异吲哚-1,3(2H)-二酮的类似物制备的,后者是我们实验室之前一份报告的主题。这些化合物被评估为血栓素(TX)合成酶抑制剂和抗高血压药物。虽然每一系列化合物都具有作为TX合成酶抑制剂和抗高血压药物的活性,但最佳化合物是N-[(1H-咪唑-1-基)烷基]喹唑啉-2,4(1H,3H)-二酮(V)。一般来说,这些化合物都是选择性酶抑制剂,至少与标准药物达唑氧苯具有同等效力。这些化合物在自发性高血压大鼠(SHR)中也表现出非常强的抗高血压活性。文中讨论了这两种活性类型的构效关系(SAR)。化合物20a在体外和体内对其他几种血小板类型的TX生成抑制特性进行了进一步评估,其效力比达唑氧苯强100至1000倍。